Filtered By:
Specialty: Cardiology
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 545 results found since Jan 2013.

Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial
Conclusions This small trial showed that SAPT (vs. DAPT) tended to reduce the occurrence of major adverse events following TAVR. SAPT reduced the risk for major or life-threatening events while not increasing the risk for MI or stroke. Larger studies are needed to confirm these results. (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation: The ARTE Trial [ARTE], NCT01559298; Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI [ARTE], NCT02640794)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - July 3, 2017 Category: Cardiology Authors: Rodes-Cabau, J., Masson, J.-B., Welsh, R. C., Garcia del Blanco, B., Pelletier, M., Webb, J. G., Al-Qoofi, F., Genereux, P., Maluenda, G., Thoenes, M., Paradis, J.-M., Chamandi, C., Serra, V., Dumont, E., Cote, M. Tags: Structural Source Type: research

Dual antiplatelet therapy is safe and efficient after left atrial appendage closure.
CONCLUSIONS: LAAC followed by DAPT seems to be a safe and efficient alternative for stroke prevention in patients with NVAF and contraindications to anticoagulation therapy. This strategy may provide a significant reduction of events such as stroke and bleeding versus the score-predicted rate. PMID: 29350390 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - January 19, 2018 Category: Cardiology Authors: Maksym J, Mazurek T, Kochman J, Grygier M, Kapłon-Cieślicka A, Marchel M, Lodziński P, Piątkowski R, Wilimski R, Czub P, Fojt A, Karolczak N, Hendzel P, Opolski G Tags: Kardiol Pol Source Type: research

Antithrombotic treatment in acute coronary syndrome and atrial fibrillation.
Authors: Darius H, Görge G, Spiecker M, Schinzel H Abstract The number of patients with atrial fibrillation (AF) is increasing due to the aging of the population. In addition, the number of patients with AF and indications for oral anticoagulation (OAC) for the prevention of stroke, who need dual antiplatelet treatment (DAPT) with acetylsalicylic acid (ASA) plus a P2Y12 inhibitor because of an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) is also increasing. In the past these patients received a triple therapy (TT) for 3-12 months. This TT has never been studied for efficacy; how...
Source: Herz - January 30, 2019 Category: Cardiology Tags: Herz Source Type: research

Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel.
In this study, we aimed to assess the association between PPIs and cerebro-cardiovascular outcomes independent of clopidogrel.Systematic searches were conducted in the Cochrane Library, PubMed, and Embase databases for all relevant studies up to August 2018. Odds ratios (ORs) with its 95% confidence intervals (CIs) were abstracted and pooled using the random-effects model.A total of 14 observational studies (13 cohort studies and 1 case-control study) were identified. Compared with non-PPI users, PPI users experienced higher risks of stroke (OR: 1.22, 95% CI: 1.08-1.36), myocardial infarction (MI; OR: 1.23, 95% CI: 1.14-1....
Source: International Heart Journal - July 18, 2019 Category: Cardiology Tags: Int Heart J Source Type: research

Antiplatelets and Vascular Dementia: A Systematic Review
J Aging Res. 2022 Sep 19;2022:9780067. doi: 10.1155/2022/9780067. eCollection 2022.ABSTRACTVascular dementia (VD) is a neurocognitive disorder whose precise definition is still up for debate. VD generally refers to dementia that is primarily caused by cerebrovascular disease or impaired cerebral blood flow. It is a subset of vascular cognitive impairment, a class of diseases that relate any cerebrovascular injury as a causal or correlating factor for cognitive decline, most commonly seen in the elderly. Patients who present with both cognitive impairment and clinical or radiologic indications of cerebrovascular pathology s...
Source: Atherosclerosis - October 17, 2022 Category: Cardiology Authors: Peter Alexander Shakthi Visagan Sara Jawhar Amogh Kare Noor Issa Reem Issa Abbas Jawhar Sneha Thomas Vasavi Gorantla Source Type: research

Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention
Conclusions: In real-life AF patients with indication for multiple antithrombotic drugs after MI/PCI, OAC and clopidogrel was equal or better on both benefit and safety outcomes compared to triple therapy.
Source: Journal of the American College of Cardiology - June 10, 2013 Category: Cardiology Authors: Morten Lamberts, Gunnar H. Gislason, Jonas Bjerring Olesen, Søren Lund Kristensen, Anne-Marie Schjerning Olsen, Anders Mikkelsen, Christine Benn Christensen, Gregory Y.H. Lip, Lars Køber, Christian Torp-Pedersen, Morten Lock Hansen Tags: Coronary Artery Disease Source Type: research

Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation: A Randomized Controlled Trial.
CONCLUSIONS: Among patients who were on 12-month dual antiplatelet therapy without complications, an additional 24 months of dual antiplatelet therapy versus aspirin alone did not reduce the risk of the composite end point of death from cardiac causes, myocardial infarction or stroke. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Identifier: NCT01186146. PMID: 24097439 [PubMed - as supplied by publisher]
Source: Circulation - October 4, 2013 Category: Cardiology Authors: Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Han S, Lee SG, Seong IW, Rha SW, Jeong MH, Lim DS, Yoon JH, Hur SH, Choi YS, Yang JY, Lee NH, Kim HS, Lee BK, Kim KS, Lee SU, Chae JK, Cheong SS, Suh IW, Park HS, Nah DY, Jeon DS, Seung KB, Lee K, Tags: Circulation Source Type: research

Biomarkers in Relation to the Effects of Ticagrelor Compared with Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with or without In-Hospital Revascularization: A Substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial.
CONCLUSIONS: Hs-TnT, NT-proBNP and GDF-15 are predictors of CV-death, MI and stroke in patients with NSTE-ACS managed non-invasively and NT-proBNP and GDF-15 also in those managed invasively. Elevated hs-TnT predicts substantial benefit of ticagrelor over clopidogrel both in invasively and non-invasively managed patients, while no apparent benefit was seen at normal hs-TnT. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Identifier: NCT00391872. PMID: 24170388 [PubMed - as supplied by publisher]
Source: Circulation - October 29, 2013 Category: Cardiology Authors: Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK, for the PLATO study group Tags: Circulation Source Type: research

Updates in Antiplatelet Agents Used in Cardiovascular Diseases
Conclusions: In the last 5 years, newer antiplatelet agents, including prasugrel and ticagrelor, have been demonstrated to reduce recurrent cardiovascular events compared to standard therapy and, however, also caused increase bleeding in selected patient populations. Newer agents including shorter acting P2Y12 inhibitor or antiplatelets that target other receptors are being evaluated to improve/maintain therapeutic efficacy yet minimize the risk of bleeding.
Source: Journal of Cardiovascular Pharmacology and Therapeutics - November 8, 2013 Category: Cardiology Authors: Cheng, J. W. M. Tags: Cardiovascular Pharmacology Core Reviews Source Type: research

Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome
Conclusion In this contemporary, large real-life ACS population, DAPT for more than 3 months compared with a shorter duration was associated with a lower risk of death, stroke, or re-infarction. Trial Registration Clinicaltrials.gov (NCT01623700).
Source: European Heart Journal - April 14, 2014 Category: Cardiology Authors: Varenhorst, C., Jensevik, K., Jernberg, T., Sundstrom, A., Hasvold, P., Held, C., Lagerqvist, B., James, S. Tags: FASTTRACK CLINICAL RESEARCH Source Type: research

0370: Effect of smoking on comparative efficacy of antithrombotic therapy in patients with atrial fibrillation. A community based cohort study
Conclusion In AF, there was a higher risk of bleeding in smokers, mainly in those treated with VKA
Source: Archives of Cardiovascular Diseases Supplements - October 12, 2014 Category: Cardiology Source Type: research

Abstract 372: Health Outcomes Associated With Triple Antiplatelet Therapy for the Secondary Prevention of Atherothrombotic Events Session Title: Poster Session III
Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of atherothrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD), based on the findings of the TRA 2°P-TIMI 50 trial for patients without a history of stroke or transient ischemic attack. This analysis evaluated the health outcomes of triple antiplatelet therapy with vorapaxar when added to a standard care regimen of clopidogrel plus aspirin (ASA) in comparison with standard care alone, for patients without a history of transient ischemic attack or ...
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Ozer-Stillman, I., Whalen, J. D., Bash, L. D., Oguz, M., Du, M., Singhal, P. K., Davies, G. M. Tags: Session Title: Poster Session III Source Type: research

Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation
The PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy) trials revealed that in atrial fibrillation (AF) patients suitable for oral anticoagulation (OAC), mechanical left atrial appendage closure (LAAC) with a catheter-delivered heart implant device (Watchman; Boston Scientific, Marlborough, Massachusetts) is effective for stroke prevention (1,2). Importantly, these patients received at least 6 weeks ...
Source: Journal of the American College of Cardiology - May 3, 2016 Category: Cardiology Source Type: research

Association Between Very Low Levels of High‐Density Lipoprotein Cholesterol and Long‐term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial
ConclusionsMedically managed ACS patients with very low baseline HDL‐C levels have higher risk of long‐term cardiovascular and all‐cause death but similar risks for nonfatal ischemic outcomes vs patients with higher baseline HDL‐C.
Source: Clinical Cardiology - March 31, 2016 Category: Cardiology Authors: Emil Hagström, Matthew T. Roe, Gail Hafley, Megan L. Neely, Mandeep S. Sidhu, Kenneth J. Winters, Dorairaj Prabhakaran, Harvey D. White, Paul W. Armstrong, Keith A.A. Fox, E. Magnus Ohman, William E. Boden, Tags: Clinical Investigations Source Type: research

Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients
Conclusions Patients receiving clopidogrel before admission for ACS and subsequently treated only medically are at higher risk for CV events versus those not previously receiving clopidogrel. More potent antiplatelet inhibition with prasugrel versus clopidogrel did not significantly reduce this risk. Trial registration number NCT00699998.
Source: Heart - July 10, 2016 Category: Cardiology Authors: Chin, C. T., Boden, W. E., Roe, M. T., Neely, B., Neely, M. L., Leiva-Pons, J. L., Corbalan, R., Gottlieb, S., Dalby, A. J., Armstrong, P. W., Prabhakaran, D., Fox, K. A. A., White, H. D., Ohman, E. M., Winters, K. J., Schiele, F. Tags: Drugs: cardiovascular system, Acute coronary syndromes Special populations Source Type: research